Evolus rises after preliminary Q4 revenue beats estimates

Evolus

21/01/2025 15:17

** Shares of cosmetic drugmaker Evolus  EOLS.O  rise ~33% to
$14
    ** Co says it expects Q4 rev. Of $79 mln, above analyst
estimates of $77.1 mln - data compiled by LSEG
    ** Co forecasts 2025 rev. to be between $345 mln and $355
mln vs. analyst est. of $350.1 mln
    ** Co says it expects to receive FDA approval for its
injectable hyaluronic acid, Evolysse, within the next 90 days
and plans to launch in the U.S. in Q2 2025
    ** All 7 brokerages covering the stock rate it "buy" or
higher; their median PT is $25 - LSEG
    ** EOLS gained 10.5% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))